- Home
- CORT
as of 03-06-2026 3:40pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.7B | IPO Year: | 2001 |
| Target Price: | $105.20 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | 0.82 | EPS Growth: | -33.33 |
| 52 Week Low/High: | $28.66 - $117.33 | Next Earning Date: | 05-25-2026 |
| Revenue: | $761,407,000 | Revenue Growth: | 12.79% |
| Revenue Growth (this year): | 29.97% | Revenue Growth (next year): | 30.25% |
| P/E Ratio: | 41.57 | Index: | N/A |
| Free Cash Flow: | 141.8M | FCF Growth: | -27.71% |
AI-Powered CORT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
Chief Development Officer
Avg Cost/Share
$40.87
Shares
20,000
Total Value
$817,334.00
Owned After
1,235
SEC Form 4
Chief Development Officer
Avg Cost/Share
$35.18
Shares
20,000
Total Value
$703,656.00
Owned After
1,235
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Guyer William | CORT | Chief Development Officer | Feb 3, 2026 | Sell | $40.87 | 20,000 | $817,334.00 | 1,235 | |
| Guyer William | CORT | Chief Development Officer | Jan 6, 2026 | Sell | $35.18 | 20,000 | $703,656.00 | 1,235 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 24, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 24, 2026 · 100% conf.
1D
+5.02%
$38.31
5D
+8.62%
$39.62
20D
+11.34%
$40.62
cort-202602240001088856false00010888562026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 24, 2026 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter)
Delaware 000-5067977-0487658
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
101 Redwood Shores Parkway, Redwood City, CA 94065 (Address of Principal Executive Offices) (Zip Code) (650) 327-3270 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueCORTThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. On February 24, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2025 and a corporate update. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein. Item 9.01. Financial Statements and Exhibits (d) Exhibits
Exhibits No.Description 99.1 Press Release of Corcept Therapeutics Incorporated, dated February 24, 2026
104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORCEPT THERAPEUTICS INCORPORATED
Date:February 24, 2026By:/s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
Q3 2025 Earnings
8-KNov 4, 2025
cort-202511040001088856false00010888562025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter)
Delaware 000-5067977-0487658
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
101 Redwood Shores Parkway, Redwood City, CA 94065 (Address of Principal Executive Offices) (Zip Code) (650) 327-3270 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueCORTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. On November 4, 2025, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and a corporate update. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein. Item 9.01. Financial Statements and Exhibits (d) Exhibits
Exhibits No.Description 99.1 Press Release of Corcept Therapeutics Incorporated, dated November 4, 2025
104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORCEPT THERAPEUTICS INCORPORATED
Date:November 4, 2025By:/s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 31, 2025
Q2 2025 Earnings
8-KJul 31, 2025
cort-202507310001088856false00010888562025-07-312025-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 31, 2025 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter)
Delaware 000-5067977-0487658
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
101 Redwood Shores Parkway, Redwood City, CA 94065 (Address of Principal Executive Offices) (Zip Code) (650) 327-3270 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueCORTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. On July 31, 2025, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and a corporate update. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein. Item 9.01. Financial Statements and Exhibits (d) Exhibits
Exhibits No.Description 99.1 Press Release of Corcept Therapeutics Incorporated, dated July 31, 2025
104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORCEPT THERAPEUTICS INCORPORATED
Date:July 31, 2025By:/s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer
Compare CORT vs Leading Stocks
See how CORT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.